Micafungin: The US perspective

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 2, 2005, Pages 183-190

  Zaas, Aimee K ^a   Steinbach, William J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aspergillosis; Candidiasis; Micafungin

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; CYCLOSPORIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; NIKKOMYCIN; PROTEIN; PYRROLE; RAVUCONAZOLE; TACROLIMUS;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; CANDIDA; CANDIDIASIS; CATHETERIZATION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GROWTH INHIBITION; HEART ARRHYTHMIA; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; HYPERVOLEMIA; IN VITRO STUDY; LIVER DYSFUNCTION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEUTROPENIA; NONHUMAN; OPEN STUDY; PEDIATRICS; PROTEIN BLOOD LEVEL; RECURRENCE RISK; REVIEW; SIDE EFFECT; SPECIES DIFFERENCE; SURVIVAL RATE; UNITED STATES;

ANIMALS; ANTIFUNGAL AGENTS; CLINICAL TRIALS; HUMANS; LIPOPROTEINS; MYCOSES; PEPTIDES, CYCLIC; SAFETY;

EID: 17844380740     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.3.2.183     Document Type: Review

References (64)

1. Jarvis WK. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin. Infect. Dis. 20(6), 1526-1530 (1995).
2. Rangel-Frausto MS, Wiblin T, Blumberg HM et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin. Infect. Dis. 29(2), 253-258 (1999).
3. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a 3-year analysis. Clin. Infect. Dis. 29(2), 239-244 (1999).
4. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39(3), 309-317 (2004).
5. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect. 33(l), 23-32 (1996).
6. Baddley JW, Stroud TRP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin. Infect. Dis. 32(9), 1319-1324 (2001).
7. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem-cell transplant recipients: changes in epidemiology and risk factors. Blood 100(13), 4358-4366 (2002).
8. Wald A, Leisenring W, van Burik JA. Bowden RA. Epidemiology of aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J. Infect. Dis. 175(6), 1459-1466 (1997).
9. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin. Infect. Dis. 31(6), 1524-1528 (2000).
10. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40(3), 852-856 (2002).
11. Pfaller MA. Dickema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. Microbiol. 40(10), 3551-3557 (2002).
12. Blumberg HM, Jarvis WP, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin. Infect. Dis. 33(2), 177-186 (2001).
13. Vincent JL, Anaissie E, Bruining H et al. Epidemiology, diagnosis and treatment of systemic candida infection in surgical patients under intensive care. Intensive Care Med. 24(3), 206-216 (1998).
14. Grohskopf LA, Sinkowitz-Cochran RL, Garrett DO et al. A national point-prevalence survey of pediatric intensive care unit-acquired infections in the United States. J. Pediatr. 140(4), 432-438 (2002).
15. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem-cell transplant recipients. Clin. Infect. Dis. 34(7), 909-917 (2002).
16. Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect. Dis. Clin. North Am. 16(4), 875-894 (2002).
17. McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin. Infect. Dis. 33(5), 641-647 (2001).
18. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347(6), 408-415 (2002).
19. Leenders AC, Daenen S, Jansen RL et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-Associated invasive fungal infections. Br. J. Haematol. 103(1), 205-212 (1998).
20. Higashiyama Y, Kohno S. Micafungin: a therapeutic review. Expert Rev. Anti Infect. Ther. 2(3), 345-355 (2004).
21. Carver PL. Micafungin. Ann. Pharmacother. 38(10), 1707-1721 (2004).
22. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20(4), 121-136 (2003).
23. Ernst EJ, Roling EE, Petzold CR, Keele DJ, Klepser ME. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill and postantifungal-effect studies. Antimicrob. Agents Chemother. 46(12), 3846-3853 (2002).
24. Mikamo H, Sato Y, Tamaya T. In vitro antifungal activity of FK463, a new watersoluble echinocandin-like lipopeptide. J. Antimicrob. Chemother. 46(3), 485-487 (2000).
25. Manavathu EK, Ramesh MS, Baskaran I, Ganesan LT, Chandrasekar PH. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J. Antimicrob. Chemother. 53(2), 386-389 (2004).
26. Watabe E, Nakai T, Matsumoto S, Ikeda F, Hatano K. Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob. Agents Chemother. 47(6), 1995-1998 (2003).
27. Bowman JC, Hicks PS, Kurtz MB et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. 46(9), 3001-3012 (2002).
28. van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia. in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39(10), 1407-1416 (2004).
29. Chiou CC, Mavrogiorgos N, Tillem. E, Hector R, Walsh TJ. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob. Agent Chemother. 45(12), 3310-3321 (2001).
30. Nakai T, Uno J, Otomo K et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important molds. Chemotherapy 48(2), 78-81 (2002).
31. Petraitis V, Petraitiene R, Groll AH et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 46(6), 1857-1869(2002).
32. Nakai T, Uno J, Ikeda F, Tawara S, Nishimura Y, Miyaji M. in vitro antifungal activity of micafungin (FK463) against dimorphich fungi: comparison of yeast-like and mycelial forms. Antimicrob. Agents Chemother. 47(4), 1376-1381 (2003).
33. Jacobs P, Wood L, Du TA, Esterhuizen K. Eradication of invasive mucormycosis-effectiveness of theeEchinocandin FK463. Hematology 8(2), 119-123 (2003).
34. Serena C, Pastor FJ, Ortoneda M, Capilla J, Nolard N, Guarro J. In vitro antifungal susceptibilities of uncommon basidiomycetous yeasts. Antimicrob. Agents Chemother. 48(7), 2724-2726 (2004).
35. Feldmesser M, Kress Y, Mednick A. Casadevall A. The effect of the echinocandin analog caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J. Infect. Dis. 182 (6), 1791-1795 (2000).
36. Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Onishi J, Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimirob. Agents Chemother. 38(7), 1480-1489 (1994).
37. Groll AH, Mickiene D, Petraitis V et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob. Agents Chemother. 45(12), 3322-3327 (2001).
38. Niwa T, Yokota Y, Tokunaga A et al. Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol. Pharm. Bull. 27(7), 1154-1156 (2004).
39. Luque JC, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob. Agents Chemother. 47(4), 1452-1455 (2003).
40. Heimenz J, Cagnoni P, Simpson D, Devine S, Chao N. Maximum tolerated dose and pharmacokinetics of FK463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem-cell transplant patients. Proceedings from the 39th ICAAC Meeting. San Francisco, CA, USA, 26-29 September 1999.
41. Ikeda F, Wakai Y, Matsumoto S et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother. 44(3), 614-618 (2000).
42. Tawara S, Ikeda F, Maki K et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 44(1), 57-62 (2000).
43. Azuma J, Yamamoto I, Ogura M, Mukai T, Suematsu H, Kageyama H. Phase I study of FK463, a new antifungal agent, in healthy adult male volunteers. Proceeding from the 38th ICAAC Meeting. San Diego, CA, USA, 24-27 September 1998.
44. Townsend R, Hebert M, Dessimoz M, Wisemandle W, Bekersky I. Pharmacokinetics of micafungin, an echinocandin antifungal, in subjects with severe renal dysfunction. Proceedings from the 31st Annual American College of Clinical Pharmacology Meeting. San Francisco, CA, USA, 21-23 September 2002.
45. Townsend F, Hebert M, Dessimoz M, Wisemandle W, Bekersky I. Pharmacokinetics of micafungin, an echinocandin antifungal, in subjects with moderate hepatic dysfunction. Proceedings from the 31st Annual American College of Clinical Pharmacology Meeting. San Francisco, CA, USA, 21-23 September 2002.
46. Townsend R, Hebert M, Wisemandle W, Bekersky I. Concomitant pharmacokinetics of micafungin, an echinocandin antifungal, and tacrolimus in healthy volunteers. Proceedings from the 31st Annual American College of Clinical Pharmacology Meeting. San Francisco, CA. USA, 21-23 September 2004.
47. Townsend R. Hebert M, Wisemandle W, Bekersky I. Concomitant pharmacokinetics of micafungin, an echinocandin antifungal, and cyclosporine in healthy volunteers. Procedings from the 31st Annual American College of Clinical Pharmacology Meeting. San Francisco, CA, USA, 21-23 September 2004.
48. Townsend R, Bekersky I, Buell DN, Seibel N. Pharmacokinetic (PK) evaluation of echinocandin FK463 in pediatric and adult patients. Proceedings from the 11th Focus on Fungus Meeting. Chicago, IL USA, 14-16 March 2001.
49. Heresi GP, Gerstmann DR, Blumer JL et al. Pharmacokinetic study of micafungin in premature neonates. Pediatric Academic Society Meeting. Seattle, WA, USA, 3-6 May 2003.
50. de Wet N, Llanos-Cuentas A. Suleiman J et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin. Infect. Dis. 39(6), 842-949 (2004).
51. Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D. Succesfull treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment. Pharmacol. Ther. 20(4), 475-481 (2004).
52. Krause DS, Simjee AE, van Rensburg C et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. 39(6), 770-775 (2004).
53. Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 113(4), 294-299 (2002).
54. Ratanatharathorn V, Flynn P, van-Burik JH, McSweeney P, Niederweiser D, Kontoyiannis D. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients. Precedings from the 44th Ameriam Society of Hematology (ASH) Meeting. PA, USA, 6-10 December 2002.
55. Anaissie E, Ostrosky-Zeichner L, Kontoyiannis D et al. Micafungin, an echinocandin antifungal agent for the treatment of new and refractory candidemia. Proceeding from the 13th Focus on Fungal Infections Meeting. Maui Hawaii, USA, 19-21 March 2003.
56. Kontoyiannis D, Buell DN, Frisbee-Hume S, Reddy BT, Rolston KVI. Initial experience with FK463 for the treatment of candidemia in cancer patients. Proceedings from the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 16-19 December 2001.
57. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347(25), 2020-2029 (2002).
58. Undre NA, Stevenson P, Amakye DD. Rifampicin and ritonavir do not affect die pharmacokinetics of micafungin (FK463), an echinocandin antifungal. Proceeding of the 14th European Conference of Clinical Microbiology and Infectious Diseases Meeting (ECCMID). Prague, Czech Republic, 1-4 May 2004.
59. Laverdiere M, Restieri C, Habel F. In vitro activity of newer antifungal agens against invasive yeast isolates from cancer patients. Proceeding from the 40th Annual Interscience Cenference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada, 17-20 September 2000. (Abstract 365).
60. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimirob. Agents Chemother. 46(6), 1773-1780 (2002).
61. Dennis C, Failing C, Greco WR et al. Combination therapy with micafungin and amphotericin B desoxycholate prolongs survival in the P47phox-deficient mouse model of chronic granulomatous disease with experimental pulmonary aspergillosis. Proceedings from the 14th Focus on Fungal Infections Meeting. New Orleans, LA, USA, 24-26 March 2004.
62. Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J. Antimirob. Chemother. 52(4), 656-662 (2003).
63. Petraitis V, Petraitiene R, Sarafandi AA et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole, and an echinocandin. J. Infect. Dis. 187(12), 1834-1843 (2003).
64. Petraitis V, Petraitiene P. Sarafandi AA et al. The combination of low dose amphotericin B and micafungin is comparable in activity to high dose amphotericin B alone in treatment of experimental invasive pulmonary aspergillosis. Proceedings from the 13th Focus on Fungal Infections Meeting. Maui, Hawaii, USA, 19-21 March 2003.